Latin-American trial or orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients

Diabetes, Obesity and Metabolism

Volumn 5, Issue 3, 2003, Pages 180-188

  Halpern, Alfredo ^a   Mancini, M C ^a   Suplicy, H ^b   Zanella, M T ^c   Repetto, G ^d   Gross, J ^e   Jadzinsky, M ^f   Barranco, J ^g   Aschner, P ^h   Ramirez, L ⁱ   Matos, A G ^j  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^f HOSPITAL DURAND   (Argentina)

^g INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^h Association Colombiana de Diabetes   (Colombia)

ⁱ Inst Costarricence Invest Clinicas   (Costa Rica)

^j Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

more..

Author keywords

Diabetes; Obesity; Orlistat

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRY; ARTICLE; BEHAVIOR THERAPY; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LABORATORY TEST; LIPID ANALYSIS; LOW CALORY DIET; MALE; METABOLIC PARAMETERS; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SOUTH AND CENTRAL AMERICA; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0037406461     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2003.00262.x     Document Type: Article

References (35)

1. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and prevalence of obesity in the United States: prevalence and trends, 1960-94. Int J Obes 1998; 22: 39-47.
2. Laurier D, Guiguet M, Chan NP, Wells JA, Valleron A-J. Prevalence of obesity: a comparative survey in France, the United Kingdom and the United States. Int J Obes 1992; 16: 565-572.
3. Kuskowa-Wolk A, Bergström R. Trends in body mass index and prevalence of obesity in Swedish women 1980-89. J Epidemiol Commun Health 1993; 47: 195-199.
4. Seidell JC. Time trends in obesity: an epidemiological perspective. Horm Metab Res 1997; 29: 155-158.
5. Monteiro CA, Mondini L, Souza ALM, Popkin BM. The nutrition transition in Brazil. Eur J Clin Nutr 1995; 49: 105-113.
6. Bray GA. Health hazards of obesity. Endocrinol Metab Clin North Am 1996; 25: 907-919.
7. Rabinowitz D, Zierler KL. Forearm metabolism in obesity and its response to intraarterial insulin. Characterization of insulin resistance and evidence for adaptative hyperinsulinism. J Clin Invest 1962; 12: 2173-2181.
8. Golay A, Felber JP, Jéquier E, DeFronzo RA, Ferranini E. Metabolic basis of obesity and non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 1988; 4: 727-747.
9. Ludvik B, Nolan JJ, Baloga J, Sacks D, Olefsky J. Effect of obesity on insulin resistance in normal subjects and patients with NIDDM. Diabetes 1995; 44: 1121-1125.
10. Lillioja S, Mott DM, Spraul M et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima indians. N Engl J Med 1993; 329: 1988-1992.
11. Pi-Sunyer F. Weight and non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1996; 63 (Suppl. 3): 426S-429S.
12. Colditz G, Willett W, Rotnitzky A, Manson J. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-486.
13. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes 1992; 16: 397-415.
14. Wing R, Koeske R, Epstein L, Nowalk M, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987; 147: 1749-1753.
15. Hollander PA, Elbein SC, Hirsch IB et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998; 21: 1288-1294.
16. UKPDS Group. United Kingdom Prospective Diabetes Study (UKPDS). 13. Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes mellitus followed for three years. BMJ 1995; 310: 83-88.
17. Goldstein D, Potvin J. Long-term weight loss. The effect of pharmacologic agents. Am J Clin Nutr 1994; 60: 647-657.
18. Manson JE, Faich GA. Pharmacotherapy for obesity - do the benefits outweight the risks? N Engl J Med 1996; 335: 659-660.
19. Stunkard AJ, Craighead LW, O'Brien R. Controlled trial of behavioural therapy, pharmacotherapy and their combination in the treatment of obesity. Lancet 1980; ii: 1045-1047.
20. Wing R, Venditti E, Jakicic J et al. Lifestyle intervention in overweight individuals with a family history of diabetes. Diabetes Care 1998; 21: 350-360.
21. Drent ML, Larsson I, William-Olsson T et al. Orlistat (Ro-18-0647), a lipase inhibitor in the treatment of human obesity; a multiple dose study. Int J Obes 1995; 19: 221-226.
22. Tonstad S, Pometta D, Erkelens D et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994; 46: 405-410.
23. Zhi J, Melia A, Funk C et al. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol 1996; 36: 1006-1011.
24. Sjöstrom L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-172.
25. Davidson MH, Hauptman J, DiGirolamo M et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat - a randomized controlled trial. JAMA 1999; 281: 235-242.
26. James WPT, Schofield EC. Human energy requirements. A manual for planners and nutritionalists. Published by Arrangements with the Food and Agriculture Organization of the United Nations. Oxford: Oxford University Press, 1990.
27. Winer BJ. Statistical Principles in Experimental Design, 2nd edn. New York: Mc-Graw-Hill, 1971.
28. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO, Geneva, 1997.
29. Pouliot M. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue. Am J Cardiol 1994; 73: 460-467.
30. Despres J, Lamarche B, Mauriege P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
31. Landsberg L. Hyperinsulinemia: possible role in obesity-induced hypertension. Hypertension 1992; 19 (Suppl.): 161-166.
32. Zhi J, Melia AT, Guerciolini R et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmac Ther 1994; 56: 82-85.
33. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens 1998; 16: 2013-2017.
34. Muls E, Kolanowski J, Schoen A, Van Gaal L, for the ObelHyx (Obesity Linked with Hypercholesterolemia treated with Xenical) Study Group. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes 2001; 25: 1713-1721.
35. Finer N. Present and future pharmacological approaches. Br Med Bull 1997; 53: 409-432.